The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today announced 60 U.S. and international institutions selected as HIV/AIDS Clinical Trials Units (CTUs) in a newly restructured system of six HIV/AIDS clinical research networks. NIAID expects to fund additional CTUs within the next several months, bringing the total to 73.
These Clinical Trials Units will carry out the next generation of HIV/AIDS vaccine, prevention and treatment research, says NIAID Director Anthony S. Fauci, M.D. They will work with our clinical research networks in a flexible, collaborative and coordinated way to tackle the critical research questions that can help accelerate progress against the HIV/AIDS pandemic. NIAID supports the worlds largest HIV/AIDS clinical research effort.
The CTU awards represent the second step of a two-part restructuring process of NIAIDs HIV/AIDS clinical trials networks. NIAID announced the clinical investigators and institutions responsible for leading the new networks in June 2006 (see http://www3.niaid.nih.gov/news/newsreleases/2006/leadership.htm).
Each CTU is a member of one or more of the six NIAID HIV/AIDS networks: the AIDS Clinical Trials Group, the HIV Prevention Trials Network, the HIV Vaccine Trials Network, the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, the International Network for Strategic Initiatives in Global HIV Trials, and the Microbicide Trials Network.
The HIV/AIDS networks and their CTUs will pursue an integrated research approach to conducting clinical trials designed to address the highest priorities in HIV/AIDS research, including
Contact: Kathy Stover
NIH/National Institute of Allergy and Infectious Diseases